IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics files for mixed shelf of up to $300 mln
Inhibikase Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025
Brief: Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO
Inhibikase Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Brief: Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability
Inhibikase Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: SP IKT Holdings Reports 8.69% Passive Stake In Inhibikase Therapeutics Inc As Of Oct 21
Brief: Inhibikase Therapeutics Closes Up To $275 Million Financing